{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:31:21Z","timestamp":1790217081215,"version":"4.1.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T00:00:00Z","timestamp":1618790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T00:00:00Z","timestamp":1618790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s10072-021-05258-3","type":"journal-article","created":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T14:03:10Z","timestamp":1618840990000},"page":"615-624","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Spinal muscular atrophy: state of the art and new therapeutic strategies"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7994-3391","authenticated-orcid":false,"given":"Sonia","family":"Messina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Sframeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adele","family":"D\u2019Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Comi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,19]]},"reference":[{"key":"5258_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1750-1172-6-71","volume":"6","author":"A D\u2019Amico","year":"2011","unstructured":"D\u2019Amico A, Mercuri E, Tiziano FD, Bertini E (2011) Spinal muscular atrophy. rphanet. J Rare Dis 6:71. https:\/\/doi.org\/10.1186\/1750-1172-6-71","journal-title":"J Rare Dis"},{"issue":"8","key":"5258_CR2","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/archneurol.2011.74","volume":"68","author":"SJ Kolb","year":"2011","unstructured":"Kolb SJ, Kissel JT (2011) Spinal muscular atrophy: a timely review. Arch Neurol 68(8):979\u2013984. https:\/\/doi.org\/10.1001\/archneurol.2011.74","journal-title":"Arch Neurol"},{"key":"5258_CR3","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1146\/annurev-genom-102319-103602","volume":"21","author":"B Wirth","year":"2020","unstructured":"Wirth B, Karakaya M, Kye MJ, Mendoza-Ferreira N (2020) Twenty-five years of spinal muscular atrophy research: from phenotype to genotype to therapy, and what comes next. Annu Rev Genomics Hum Genet 21:231\u2013261. https:\/\/doi.org\/10.1146\/annurev-genom-102319-103602","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"5258_CR4","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/ajmg.10425","volume":"110","author":"S Ogino","year":"2002","unstructured":"Ogino S, Leonard DG, Rennert H, Ewens WJ, Wilson RB (2002) Genetic risk assessment in carrier testing for spinal muscular atrophy. Am J Med Genet 110:301\u2013307. https:\/\/doi.org\/10.1002\/ajmg.10425","journal-title":"Am J Med Genet"},{"key":"5258_CR5","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/ajmg.a.33474","volume":"152A","author":"TW Prior","year":"2010","unstructured":"Prior TW, Snyder PJ, Rink BD, Pearl DK, Pyatt RE, Mihal DC, Conlan T, Schmalz B, Montgomery L, Ziegler K, Noonan C, Hashimoto S, Garner S (2010) Newborn and carrier screening for spinal muscular atrophy. Am J Med Genet A 152A:1605\u20131607","journal-title":"Am J Med Genet A"},{"key":"5258_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1053\/ejpn.1999.0184","volume":"3","author":"MJ MacLeod","year":"1999","unstructured":"MacLeod MJ, Taylor JE, Lunt PW, Mathew CG, Robb SA (1999) Prenatal onset spinal muscular atrophy. Eur J Paediatr Neurol 3:65\u201372. https:\/\/doi.org\/10.1053\/ejpn.1999.0184","journal-title":"Eur J Paediatr Neurol"},{"key":"5258_CR7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1053\/ejpn.1999.0181","volume":"3","author":"V Dubowitz","year":"1999","unstructured":"Dubowitz V (1999) Very severe spinal muscular atrophy (SMA type 0): an expanding clinical phenotype. Eur J Paediatr Neurol 3:49\u201351. https:\/\/doi.org\/10.1053\/ejpn.1999.0181","journal-title":"Eur J Paediatr Neurol"},{"key":"5258_CR8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/s0022-510x(96)00284-5","volume":"146","author":"K Zerres","year":"1997","unstructured":"Zerres K, Rudnik-Sch\u00f6neborn S, Forrest E, Lusakowska A, Borkowska J, Hausmanowa-Petrusewicz I (1997) A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients. J Neurol Sci 146:67\u201372. https:\/\/doi.org\/10.1016\/s0022-510x(96)00284-5","journal-title":"J Neurol Sci"},{"key":"5258_CR9","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/ng0797-265","volume":"16","author":"S Lefebvre","year":"1997","unstructured":"Lefebvre S, Burlet P, Liu Q, Bertrandy S, Clermont O, Munnich A, Dreyfuss G, Melki J (1997) Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet 16:265\u2013269. https:\/\/doi.org\/10.1038\/ng0797-265","journal-title":"Nat Genet"},{"issue":"208\u2013215","key":"5258_CR10","doi-asserted-by":"publisher","first-page":"s9","DOI":"10.1016\/j.nmd.2018.01.003","volume":"28","author":"M Calucho","year":"2018","unstructured":"Calucho M, Bernal S, Al\u00edas L, March F, Vencesl\u00e1 A, Rodr\u00edguez-\u00c1lvarez FJ, Aller E, Fern\u00e1ndez RM, Borrego S, Mill\u00e1n JM, Hern\u00e1ndez-Chico C, Cusc\u00f3 I, Fuentes-Prior P, Tizzano EF (2018) Correlation between SMA type and SMN2 copy number revisited: san analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases. Neuromuscul Disord 28(208\u2013215):s9\u2013s11. https:\/\/doi.org\/10.1016\/j.nmd.2018.01.003","journal-title":"Neuromuscul Disord"},{"issue":"9","key":"5258_CR11","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1136\/jmg.2010.079004","volume":"47","author":"S Bernal","year":"2010","unstructured":"Bernal S, Al\u00edas L, Barcel\u00f3 MJ, Also-Rallo E, Mart\u00ednez-Hern\u00e1ndez R, G\u00e1mez J, Guill\u00e9n-Navarro E, Rosell J, Hernando I, Rodr\u00edguez-Alvarez FJ, Borrego S, Mill\u00e1n JM, Hern\u00e1ndez-Chico C, Baiget M, Fuentes-Prior P, Tizzano EF (2010) The c.859G>C variant in the SMN2 gene is associated with types II and III SMA and originates from a common ancestor. J Med Genet 47(9):640\u2013642. https:\/\/doi.org\/10.1136\/jmg.2010.079004","journal-title":"J Med Genet"},{"issue":"1","key":"5258_CR12","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13023-020-01356-1","volume":"15","author":"E Mercuri","year":"2020","unstructured":"Mercuri E, Lucibello S, Perulli M, Coratti G, De Sanctis R, Pera MC, Pane M, Montes J, De Vivo DC, Darras BT, Kolb SJ, Finkel RS (2020) Longitudinal natural history of type I spinal muscular atrophy: a critical review. Orphanet J Rare Dis 15(1):84. https:\/\/doi.org\/10.1186\/s13023-020-01356-1","journal-title":"Orphanet J Rare Dis"},{"key":"5258_CR13","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1097\/PEP.0b013e3182351f04","volume":"23","author":"AM Glanzman","year":"2011","unstructured":"Glanzman AM, McDermott MP, Montes J, Martens WB, Flickinger J, Riley S et al (2011) Validation of the Children\u2019s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND). Pediatr Phys Ther 23:322\u2013326. https:\/\/doi.org\/10.1097\/PEP.0b013e3182351f04","journal-title":"Pediatr Phys Ther"},{"issue":"35","key":"5258_CR14","doi-asserted-by":"publisher","first-page":"35ra42","DOI":"10.1126\/scitranslmed.3000830","volume":"2","author":"CF Valori","year":"2010","unstructured":"Valori CF, Ning K, Wyles M, Mead RJ, Grierson AJ, Shaw PJ, Azzouz M (2010) Systemic delivery ofscAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy. Sci Transl Med 2(35):35ra42. https:\/\/doi.org\/10.1126\/scitranslmed.3000830","journal-title":"Sci Transl Med"},{"key":"5258_CR15","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, Lowes L, Alfano L, Berry K, Church K et al (2017) Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med 377:1713\u20131722. https:\/\/doi.org\/10.1056\/NEJMoa1706198","journal-title":"N Engl J Med"},{"key":"5258_CR16","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1212\/WNL.0000000000009372","volume":"94","author":"NL Kuntz","year":"2020","unstructured":"Kuntz NL, Pe\u00f1a LDN, Shieh PB et al (2020) Onasemnogene Abeparvovec-xioi gene-replacement therapy for spinal muscular atrophy type 1 (SMA1): phase 3 US study (STR1VE) update (1828) Presented at the American Academy of Neurology Conference 2020. Neurology 94:1828","journal-title":"Neurology"},{"key":"5258_CR17","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1101\/gad.1941310","volume":"24","author":"Y Hua","year":"2010","unstructured":"Hua Y, Sahashi K, Hung G, Rigo F, Passini MA, Bennett CF, Krainer AR (2010) Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev 24:1634\u20131644","journal-title":"Genes Dev"},{"key":"5258_CR18","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, Chiriboga CA, Saito K, Servais L, Tizzano E, Topaloglu H, Tulinius M, Montes J, Glanzman AM, Bishop K, Zhong ZJ, Gheuens S, Bennett CF, Schneider E, Farwell W, de Vivo DC (2017) Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 377:1723\u20131732","journal-title":"N Engl J Med"},{"key":"5258_CR19","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, Iannaccone ST, Kirschner J, Kuntz NL, Saito K, Shieh PB, Tulinius M, Mazzone ES, Montes J, Bishop KM, Yang Q, Foster R, Gheuens S, Bennett CF, Farwell W, Schneider E, de Vivo DC, Finkel RS (2018) Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med 378:625\u2013635","journal-title":"N Engl J Med"},{"key":"5258_CR20","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","volume":"29","author":"DC De Vivo","year":"2019","unstructured":"De Vivo DC, Bertini E, Swoboda KJ, Hwu W, Crawford TO, Finkel RS, Kirschner J, Kuntz NL, Parsons JA, Ryan MM et al (2019) Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the phase 2 NURTURE study. Neuromuscul Disord 29:842\u2013856","journal-title":"Neuromuscul Disord"},{"key":"5258_CR21","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/ana.25533","volume":"86","author":"M Pane","year":"2019","unstructured":"Pane M, Coratti G, Sansone VA, Messina S, Bruno C, Catteruccia M, Sframeli M, Albamonte E, Pedemonte M, D\u2019Amico A et al (2019) Nusinersen in type 1 spinal muscular atrophy: twelve-month real-world data. Ann Neurol 86:443\u2013451","journal-title":"Ann Neurol"},{"key":"5258_CR22","doi-asserted-by":"crossref","unstructured":"Servais L, Baranello G, Masson R, Mazurkiewicz-Be\u0142dzi\u0144ska M, Rose K, Vlodavets D, Xiong H, Zanoteli E, El-Khairi M, Fuerst-Recktenwald S, et al. (2020) FIREFISH Part 2: efficacy and safety of risdiplam (RG7916) in infants with type 1 spinal muscular atrophy (SMA). Presented at the American Academy of Neurology Conference 2020. Neurology 2020, 94, 1302","DOI":"10.1183\/13993003.congress-2020.1172"},{"issue":"94","key":"5258_CR23","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1212\/WNL.94.15_supplement.1260","volume":"2020","author":"E Mercuri","year":"2020","unstructured":"Mercuri E, Barisic N, Boespflug-Tanguy O, Deconinck N, Kostera-Pruszczyk A, Masson R, Mazzone E, Nascimento R, Osorio A, Saito K et al (2020) SUNFISH Part 2: efficacy and safety of risdiplam (RG7916) in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA) Presented at the American Academy of Neurology Conference 2020. Neurology 2020(94):1260","journal-title":"Neurology"},{"key":"5258_CR24","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.pediatrneurol.2020.01.003","volume":"109","author":"CJJ Yeo","year":"2020","unstructured":"Yeo CJJ, Darras BT (2020 Aug) (2020) Overturning the paradigm of spinal muscular atrophy as just a motor neuron disease. Pediatr. Neurol. 109:12\u201319. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2020.01.003","journal-title":"Neurol."},{"issue":"6","key":"5258_CR25","doi-asserted-by":"publisher","first-page":"e00447","DOI":"10.1002\/prp2.447","volume":"6","author":"A Poirier","year":"2018","unstructured":"Poirier A, Weetall M, Heinig K, Bucheli F, Schoenlein K, Alsenz J, Bassett S, Ullah M, Senn C, Ratni H et al (2018) Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs. Pharmacol Res Perspect 6(6):e00447. https:\/\/doi.org\/10.1002\/prp2.447","journal-title":"Pharmacol Res Perspect"},{"issue":"5","key":"5258_CR26","doi-asserted-by":"publisher","first-page":"e96921","DOI":"10.1371\/journal.pone.0096921","volume":"9","author":"DT Hwee","year":"2014","unstructured":"Hwee DT, Kennedy A, Ryans J, Russell AJ, Jia Z, Hinken AC, Morgans DJ, Malik FI, Jasper JR (2014) Fast skeletal muscle troponin activator tirasemtiv increases muscle function and performance in the B6SJL-SOD1G93A ALS mouse model. PLoS One 9(5):e96921. https:\/\/doi.org\/10.1371\/journal.pone.0096921","journal-title":"PLoS One"},{"key":"5258_CR27","doi-asserted-by":"publisher","unstructured":"Cheng AJ, Hwee DT, Kim LH, Durham N, Yang HT, Hinken AC, Kennedy AR, Terjung RL, Jasper JR, Malik FI et al Fast skeletal muscle troponin activator CK-2066260 increases fatigue resistance by reducing the energetic cost of muscle contraction. J Physiol 597(17):4615\u20134625. https:\/\/doi.org\/10.1113\/JP278235","DOI":"10.1113\/JP278235"},{"key":"5258_CR28","unstructured":"Rudnicki, S.A.; Andrews, J.A.; Malik, F.I. CY 5021 (2018) A phase 2, double-blind, randomized, placebo-controlled, multiple-dose study of reldesemtiv 2 ascending-dose cohorts of patients with Spinal Muscular Atrophy (SMA). In Proceedings of the Cure SMA 2018, Dallas, TX, USA, 16 June 2018"},{"issue":"5","key":"5258_CR29","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1093\/hmg\/ddv629","volume":"25","author":"Z Feng","year":"2016","unstructured":"Feng Z, Ling KK, Zhao X, Zhou C, Karp G, Welch EM, Naryshkin N, Ratni H, Chen KS, Metzger F et al (2016) Pharmacologically induced mouse model of adult spinal muscular atrophy to evaluate effectiveness of therapeutics after disease onset. Hum Mol Genet 25(5):964\u2013975. https:\/\/doi.org\/10.1093\/hmg\/ddv629","journal-title":"Hum Mol Genet"},{"issue":"7","key":"5258_CR30","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1093\/hmg\/ddy382","volume":"28","author":"KK Long","year":"2019","unstructured":"Long KK, O\u2019Shea KM, Khairallah RJ, Howell K, Paushkin S, Chen KS, Cote SM, Webster MT, Stains JP, Treece E et al (2019) Specific inhibition of myostatin activation is beneficial in mouse models of SMA therapy. Hum Mol Genet 28(7):1076\u20131089. https:\/\/doi.org\/10.1093\/hmg\/ddy382","journal-title":"Hum Mol Genet"},{"issue":"18","key":"5258_CR31","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1212\/WNL.0b013e318271f7e4","volume":"79","author":"P Kaufmann","year":"2012","unstructured":"Kaufmann P, McDermott MP, Darras BT et al (2012) Prospective cohort study of spinal muscular atrophy types 2 and 3. Neurology 79(18):1889\u20131897. https:\/\/doi.org\/10.1212\/WNL.0b013e318271f7e4","journal-title":"Neurology"},{"issue":"2","key":"5258_CR32","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.nmd.2015.10.006","volume":"26","author":"E Mercuri","year":"2016","unstructured":"Mercuri E, Finkel R, Montes J et al (2016) Patterns of disease progression in type 2 and 3 SMA: implications for clinical trials. Neuromuscul Disord 26(2):126\u2013131. https:\/\/doi.org\/10.1016\/j.nmd.2015.10.006","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"5258_CR33","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","volume":"28","author":"RS Finkel","year":"2018","unstructured":"Finkel RS, Mercuri E, Meyer OH et al (2018) Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord 28(3):197\u2013207. https:\/\/doi.org\/10.1016\/j.nmd.2017.11.004","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"5258_CR34","doi-asserted-by":"publisher","first-page":"e0199657","DOI":"10.1371\/journal.pone.0199657","volume":"13","author":"J Montes","year":"2018","unstructured":"Montes J, McDermott MP, Mirek E, Mazzone ES, Main M, Glanzman AM, Duong T, Young SD, Salazar R, Pasternak A, Gee R, De Sanctis R et al (2018) Ambulatory function in spinal muscular atrophy: age-related patterns of progression. PLoS One 13(6):e0199657. https:\/\/doi.org\/10.1371\/journal.pone.0199657","journal-title":"PLoS One"},{"issue":"13","key":"5258_CR35","doi-asserted-by":"publisher","first-page":"e1241","DOI":"10.1212\/WNL.0000000000008166","volume":"93","author":"E Mercuri","year":"2019","unstructured":"Mercuri E, Lucibello S, Pera MC, Carnicella S, Coratti G, De Sanctis R, Messina S, Mazzone E, Forcina N, Fanelli L, Norcia G, Antonaci L, Frongia A:L; Pane M. (2019) Long-term progression in type II spinal muscular atrophy: a retrospective observational study. Neurology 93(13):e1241\u2013e1247. https:\/\/doi.org\/10.1212\/WNL.0000000000008166","journal-title":"Neurology"},{"issue":"6","key":"5258_CR36","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1002\/ana.25900","volume":"88","author":"G Coratti","year":"2020","unstructured":"Coratti G, Messina S, Lucibello S, Pera MC, Montes J, Pasternak A, Bovis F, Exposito Escudero J, Mazzone ES, Mayhew A, Glanzman AM, Young SD et al (2020) Clinical variability in spinal muscular atrophy type III. Ann Neurol 88(6):1109\u20131117. https:\/\/doi.org\/10.1002\/ana.25900","journal-title":"Ann Neurol"},{"issue":"4","key":"5258_CR37","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/mus.26419","volume":"59","author":"MC Pera","year":"2019","unstructured":"Pera MC, Coratti G, Mazzone ES, Montes J, Scoto M, De Sanctis R, Main M, Mayhew A, Muni Lofra R, Dunaway Young S, Glanzman AM, Duong T, Pasternak A et al (2019) Revised upper limb module for spinal muscular atrophy: 12\u2009month changes. Muscle Nerve 59(4):426\u2013430. https:\/\/doi.org\/10.1002\/mus.26419","journal-title":"Muscle Nerve"},{"issue":"14","key":"5258_CR38","doi-asserted-by":"publisher","first-page":"e1988","DOI":"10.1212\/WNL.0000000000010540","volume":"95","author":"CA Wijngaarde","year":"2020","unstructured":"Wijngaarde CA, Stam M, Otto LAM, Bartels B, Asselman FL, van Eijk RPA, van den Berg LH, Goedee HS, Wadman RI, van der Pol WL (2020) Muscle strength and motor function in adolescents and adults with spinal muscular atrophy. Neurology 95(14):e1988\u2013e1998. https:\/\/doi.org\/10.1212\/WNL.0000000000010540","journal-title":"Neurology"},{"issue":"4","key":"5258_CR39","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3233\/JND-200534","volume":"7","author":"VA Sansone","year":"2020","unstructured":"Sansone VA, Walter MC, Attarian S, Delstanche S, Mercuri E, Lochm\u00fcller H, Neuwirth C, Vazquez-Costa JF, Kleinschnitz C, Hagenacker T (2020) Measuring outcomes in adults with spinal muscular atrophy - challenges and future directions - meeting report. J Neuromuscul Dis 7(4):523\u2013534. https:\/\/doi.org\/10.3233\/JND-200534","journal-title":"J Neuromuscul Dis"},{"issue":"5","key":"5258_CR40","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/acn3.406","volume":"4","author":"U Bonati","year":"2017","unstructured":"Bonati U, Holiga \u0160, Hellbach N, Risterucci C, Bergauer T, Tang W, Hafner P, Thoeni A, Bieri O, Gerlach I, Marquet A, Khwaja O, Sambataro F, Bertolino A, Dukart J, Fischmann A, Fischer D, Czech C (2017) Longitudinal characterization of biomarkers for spinal muscular atrophy. Ann Clin Transl Neurol 4(5):292\u2013304. https:\/\/doi.org\/10.1002\/acn3.406","journal-title":"Ann Clin Transl Neurol"},{"key":"5258_CR41","doi-asserted-by":"publisher","unstructured":"Totzeck A, Stolte B, Kizina K, Bolz S, Schlag M, Thimm A, Kleinschnitz C, Hagenacker T (2019) Neurofilament heavy chain and tau protein are not elevated in cerebrospinal fluid of adult patients with spinal muscular atrophy during loading with nusinersen. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms20215397","DOI":"10.3390\/ijms20215397"},{"key":"5258_CR42","doi-asserted-by":"publisher","first-page":"175628641984605","DOI":"10.1177\/1756286419846058","volume":"12","author":"CD Wurster","year":"2019","unstructured":"Wurster CD, G\u00fcnther R, Steinacker P, Dreyhaupt J, Wollinsky K, Uzelac Z, Witzel S, Kocak T, Winter B, Koch JC, Lingor P, Petri S, Ludolph AC, Hermann A, Otto M (2019) Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment. Ther Adv Neurol Disord 12:1756286419846058. https:\/\/doi.org\/10.1177\/1756286419846058","journal-title":"Ther Adv Neurol Disord"},{"issue":"4","key":"5258_CR43","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1007\/s00415-019-09646-w","volume":"267","author":"C Brogna","year":"2020","unstructured":"Brogna C, Cristiano L, Verdolotti T, Pichiecchio A, Cinnante C, Sansone V, Sconfienza LM, Berardinelli A, Garibaldi M, Antonini G, Pane M, Pera MC, Antonaci L, Ficociello L, Albamonte E, Tasca G, Begliuomini C, Tartaglione T, Maggi L, Govoni A, Comi G, Colosimo C, Mercuri E (2020) MRI patterns of muscle involvement in type 2 and 3 spinal muscular atrophy patients. J Neurol 267(4):898\u2013912. https:\/\/doi.org\/10.1007\/s00415-019-09646-w","journal-title":"J Neurol"},{"key":"5258_CR44","doi-asserted-by":"publisher","unstructured":"Faravelli I, Meneri M, Saccomanno D, Velardo D, Abati E, Gagliardi D, Parente V, Petrozzi L, Ronchi D, Stocchetti N, Calderini E, D\u2019Angelo G, Chidini G, Prandi E, Ricci G, Siciliano G, Bresolin N, Comi GP, Corti S, Magri F, Govoni A Nusinersen treatment and cerebrospinal fluid neurofilaments: an explorative study on Spinal Muscular Atrophy type 3 patients. J Cell Mol Med 24(5):3034\u20133039. https:\/\/doi.org\/10.1111\/jcmm.14939","DOI":"10.1111\/jcmm.14939"},{"key":"5258_CR45","doi-asserted-by":"publisher","first-page":"117067","DOI":"10.1016\/j.jns.2020.117067","volume":"417","author":"A Barp","year":"2020","unstructured":"Barp A, Carraro E, Albamonte E, Salmin F, Lunetta C, Comi GP, Messina C, Albano D, Chianca V, Sconfienza LM, Mercuri EM, Sansone VA (2020) Muscle MRI in two SMA patients on nusinersen treatment: a two years follow-up. J Neurol Sci 417:117067. https:\/\/doi.org\/10.1016\/j.jns.2020.117067","journal-title":"J Neurol Sci"},{"issue":"13","key":"5258_CR46","doi-asserted-by":"publisher","first-page":"e1206","DOI":"10.1212\/WNL.0000000000006241","volume":"91","author":"P Mongiovi","year":"2018","unstructured":"Mongiovi P, Dilek N, Garland C, Hunter M, Kissel JT, Luebbe E, McDermott MP, Johnson N, Heatwole C (2018) Patient reported impact of symptoms in spinal muscular atrophy (PRISM-SMA). Neurology. 91(13):e1206\u2013e1214. https:\/\/doi.org\/10.1212\/WNL.0000000000006241","journal-title":"Neurology."},{"issue":"4","key":"5258_CR47","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3233\/JND-190416","volume":"6","author":"MC Walter","year":"2019","unstructured":"Walter MC, Wenninger S, Thiele S, Stauber J, Hiebeler M, Greckl E, Stahl K, Pechmann A, Lochm\u00fcller H, Kirschner J, Schoser B (2019) Safety and treatment effects of nusinersen in longstanding adult 5q-SMA type 3 - a prospective observational study. J Neuromuscul Dis 6(4):453\u2013465. https:\/\/doi.org\/10.3233\/JND-190416","journal-title":"J Neuromuscul Dis"},{"issue":"2","key":"5258_CR48","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/mus.26769","volume":"61","author":"A Veerapandiyan","year":"2020","unstructured":"Veerapandiyan A, Eichinger K, Guntrum D, Kwon J, Baker L, Collins E, Ciafaloni E (2020) Nusinersen for older patients with spinal muscular atrophy: a real-world clinical setting experience. Muscle Nerve 61(2):222\u2013226. https:\/\/doi.org\/10.1002\/mus.26769","journal-title":"Muscle Nerve"},{"key":"5258_CR49","doi-asserted-by":"publisher","first-page":"175628642090780","DOI":"10.1177\/1756286420907803","volume":"13","author":"E Jochmann","year":"2020","unstructured":"Jochmann E, Steinbach R, Jochmann T et al (2020) Experiences from treating seven adult 5q spinal muscular atrophy patients with nusinersen. Ther Adv Neurol Disord 13:1756286420907803. https:\/\/doi.org\/10.1177\/1756286420907803","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"5258_CR50","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3233\/JND-190453","volume":"7","author":"CJJ Yeo","year":"2020","unstructured":"Yeo CJJ, Simeone SD, Townsend EL, Zhang RZ, Swoboda KJ (2020) Prospective cohort study of nusinersen treatment in adults with spinal muscular atrophy. J Neuromuscul Dis 7(3):257\u2013268. https:\/\/doi.org\/10.3233\/JND-190453","journal-title":"J Neuromuscul Dis"},{"issue":"4","key":"5258_CR51","doi-asserted-by":"publisher","first-page":"e413","DOI":"10.1212\/WNL.0000000000009914","volume":"95","author":"O Moshe-Lilie","year":"2020","unstructured":"Moshe-Lilie O, Visser A, Chahin N, Ragole T, Dimitrova D, Karam C (2020) Nusinersen in adult patients with spinal muscular atrophy: observations from a single center. Neurology. 95(4):e413\u2013e416. https:\/\/doi.org\/10.1212\/WNL.0000000000009914","journal-title":"Neurology."},{"issue":"4","key":"5258_CR52","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","volume":"19","author":"T Hagenacker","year":"2020","unstructured":"Hagenacker T, Wurster CD, G\u00fcnther R et al (2020) Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional,multicentre, observational cohort study. Lancet Neurol 19(4):317\u2013325. https:\/\/doi.org\/10.1016\/S1474-4422(20)30037-5","journal-title":"Lancet Neurol"},{"issue":"11","key":"5258_CR53","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1136\/jnnp-2020-323822","volume":"91","author":"L Maggi","year":"2020","unstructured":"Maggi L, Bello L, Bonanno S, Govoni A, Caponnetto C, Passamano L, Grandis M, Trojsi F, Cerri F, Ferraro M, Bozzoni V, Caumo L et al (2020) Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3. J Neurol Neurosurg Psychiatry 91(11):1166\u20131174. https:\/\/doi.org\/10.1136\/jnnp-2020-323822","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"5258_CR54","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.nmd.2020.07.007","volume":"30","author":"CA Chiriboga","year":"2020","unstructured":"Chiriboga CA, Marra J, LaMarca NM, Young SD, Weimer LH, Levin B, McCabe B (2020) Lack of effect on ambulation of dalfampridine-ER (4-AP) treatment in adult SMA patients. Neuromuscul Disord 30(8):693\u2013700. https:\/\/doi.org\/10.1016\/j.nmd.2020.07.007","journal-title":"Neuromuscul Disord"},{"key":"5258_CR55","doi-asserted-by":"publisher","first-page":"898","DOI":"10.3389\/fneur.2019.00898","volume":"10","author":"DST Kariyawasam","year":"2019","unstructured":"Kariyawasam DST, D\u2019Silva A, Lin C, Ryan MM, Farrar MA (2019) Biomarkers and the development of a personalized medicine approach in spinal muscular atrophy. Front Neurol 10:898. https:\/\/doi.org\/10.3389\/fneur.2019.00898","journal-title":"Front Neurol"},{"issue":"9","key":"5258_CR56","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1007\/s00415-019-09389-8","volume":"266","author":"B Olsson","year":"2019","unstructured":"Olsson B, Alberg L, Cullen NC, Michael E, Wahlgren L, Kroksmark AK, Rostasy K, Blennow K, Zetterberg H, Tulinius M (2019) NFL is a marker of treatment response in children with SMA treated with nusinersen. J Neurol 266(9):2129\u20132136. https:\/\/doi.org\/10.1007\/s00415-019-09389-8","journal-title":"J Neurol"},{"key":"5258_CR57","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/acn3.779","volume":"6","author":"BT Darras","year":"2019","unstructured":"Darras BT, Crawford TO, Finkel RS, Mercuri E, De Vivo DC, Oskoui M, Tizzano EF, Ryan MM, Muntoni F, Zhao G et al (2019) Neurofilament as a potential biomarker for spinal muscular atrophy. Ann Clin Transl Neurol 6:932\u2013944. https:\/\/doi.org\/10.1002\/acn3.779","journal-title":"Ann Clin Transl Neurol"},{"key":"5258_CR58","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1172\/JCI131989","volume":"130","author":"J Jeong-Ki Kim","year":"2020","unstructured":"Jeong-Ki Kim J, Jha N, Feng Z, Faleiro MR, Chiriboga CA, Wei-Lapierre A, Dirksen RT, Ko C, Monani UR (2020) Muscle-specific SMN reduction reveals motor neuron-independent disease in spinal muscular atrophy models. J Clin Invest 130:1271\u20131287. https:\/\/doi.org\/10.1172\/JCI131989","journal-title":"J Clin Invest"},{"key":"5258_CR59","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1001\/jamaneurol.2015.0178","volume":"72","author":"M Ripolone","year":"2015","unstructured":"Ripolone M, Ronchi D, Violano R, Vallejo D, Fagiolari G, Barca E, Lucchini V, Colombo I, Villa L, Berardinelli A, Balottin U, Morandi L, Mora M, Bordoni A, Fortunato F, Corti S, Parisi D, Toscano A, Sciacco M, DiMauro S, Comi GP, Moggio M (2015) Impaired muscle mitochondrial biogenesis and myogenesis in spinal muscular atrophy. JAMA Neurol 72:666\u2013675. https:\/\/doi.org\/10.1001\/jamaneurol.2015.0178","journal-title":"JAMA Neurol"},{"key":"5258_CR60","doi-asserted-by":"publisher","unstructured":"Montes J, Goodwin AM, McDermott MP, Uher D, Hernandez FM, Coutts K, Cocchi J, Hauschildt M, Cornett KM, Rao AK, Monani UR, Ewing GC, de Vivo DC (2021) Diminished muscle oxygen uptake and fatigue in spinal muscular atrophy. Ann Clin Transl Neurol. Online ahead of print. https:\/\/doi.org\/10.1002\/acn3.51353","DOI":"10.1002\/acn3.51353"},{"issue":"5","key":"5258_CR61","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1007\/s12325-019-00923-8","volume":"36","author":"O Dabbous","year":"2019","unstructured":"Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Gu\u00e9rin A, Pivneva I, Wu EQ, Arjunji R, Feltner D, Sproule DM (2019) Survival, motor function, and motor milestones: comparison of AVXS-101 relative to nusinersen for the treatment of infants with spinal muscular atrophy type 1. Adv Ther 36(5):1164\u20131176. https:\/\/doi.org\/10.1007\/s12325-019-00923-8","journal-title":"Adv Ther"},{"key":"5258_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JND-190424","volume":"7","author":"DC Schorling","year":"2020","unstructured":"Schorling DC, Pechmann A, Kirschner J (2020) Advances in treatment of spinal muscular atrophy\u2014new phenotypes, new challenges, new implications for care. J Neuromuscul Dis 7:1\u201313. https:\/\/doi.org\/10.3233\/JND-190424","journal-title":"J Neuromuscul Dis"},{"key":"5258_CR63","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1590\/1980-57642018dn13-040011","volume":"13","author":"GJ Polido","year":"2019","unstructured":"Polido GJ, de Miranda MMV, Carvas N, Mendon\u00e7a RH, Caromano FA, Reed UC, Zanoteli E, Voos MC (2019) Cognitive performance of children with spinal muscular atrophy: a systematic review. Dement Neuropsychol 13:436\u2013443. https:\/\/doi.org\/10.1590\/1980-57642018dn13-040011","journal-title":"Dement Neuropsychol"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-021-05258-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-021-05258-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-021-05258-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T18:50:14Z","timestamp":1724871014000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-021-05258-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,19]]},"references-count":63,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["5258"],"URL":"https:\/\/doi.org\/10.1007\/s10072-021-05258-3","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,19]]},"assertion":[{"value":"26 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}